Akorn Inc (AKRX) 26.47 $AKRX
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 237.42 (+2.88), GNRX: 24.40 (-0.14), PRGO: 90.36 (-0.63), AXGN: 8.85 (-0.16), AKRX: 26.47 (-0.45), MYL: 41.82 (-0.54), TEVA: 51.00 (+0.61), AMPH: 18.73 (-0.27), NVS: 78.26 (-0.51)
Akorn Relaunches Ofloxacin Otic Solution
GlobeNewswire - Thu Aug 25, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has relaunched Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use.
AKRX: 26.47 (-0.45)
Akorn to Present at Morgan Stanley Global Healthcare Conference
GlobeNewswire - Wed Aug 24, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn's CEO, Raj Rai, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference.
AKRX: 26.47 (-0.45), MS: 31.81 (-0.25)
Akorn Appoints Robert Monahan as Senior Vice President of Corporate Development
GlobeNewswire - Thu Aug 18, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Rob Monahan has recently joined Akorn as Senior Vice President of Corporate Development.
WBA: 81.39 (+0.68), AKRX: 26.47 (-0.45)
Akorn Set to Possibly Rebound After Yesterday's Selloff of 1.91%
Comtex SmarTrend(R) - Wed Aug 10, 3:21PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $29.50 to a high of $31.00. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $30.11 on volume of 726,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 26.47 (-0.45)
Akorn Set to Possibly Rebound After Yesterday's Selloff of 4.36%
Comtex SmarTrend(R) - Thu Aug 04, 1:30PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $31.50 to a high of $35.40. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $32.41 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 26.47 (-0.45)
Downgrade Alert for Akorn (AKRX)
Comtex SmarTrend(R) - Wed Aug 03, 3:48AM CDT
Akorn (NASDAQ:AKRX) was downgraded from Outperform to Market Perform at Raymond James today. The stock closed yesterday at $32.89 on volume of 1.5 million shares, below average daily volume of 1.5 million. Akorn, Inc. develops, manufactures, and markets ophthalmic and injectable pharmaceutical products. The Company sells various diagnostic and therapeutic pharmaceutical products focused primarily on ophthalmology, anesthesia, antidotes, and rheumatology. Akorn also markets ophthalmic surgical instruments and other supplies, and provides contract manufacturing for third parties.
AKRX: 26.47 (-0.45)
Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.24 (-0.10), CPRX: 0.94 (-0.07), AKRX: 26.47 (-0.45), PCRX: 40.00 (+0.37)
Akorn Updates Form S-8 Status by Filing Form 10-Q's for First, Second and Third Quarters of 2015
GlobeNewswire - Thu Jun 02, 5:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has filed quarterly reports on Forms 10-Q with the Securities and Exchange Commission (SEC) for the quarters ended March 31, 2015, June 30, 2015 and September 30, 2015. The quarterly financial results that are included in the individual Forms 10-Q were previously filed by the Company in its comprehensive Form 10-K for the fiscal year 2015 that was filed with the SEC on May 10, 2016. The individual Forms 10-Q were filed solely in order to make effective the Company's Registration Statement on Form S-8, on which the Company's securities offered under its employee benefit plan are registered.
AKRX: 26.47 (-0.45)
Akorn to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that management will be presenting at the Jefferies 2016 Healthcare Conference and William Blair 36th Annual Growth Stock Conference in June.
AKRX: 26.47 (-0.45)
SmarTrend Watching for Potential Rebound in Shares of Akorn After 2.24% Loss
Comtex SmarTrend(R) - Thu May 26, 2:05PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $29.37 to a high of $30.51. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $30.27 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 26.47 (-0.45)
Akorn (AKRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:54AM CDT
As of late, it has definitely been a great time to be an investor in Akorn, Inc. (AKRX)
AKRX: 26.47 (-0.45)
Watch for Akorn to Potentially Pullback After Gaining 7.19% Yesterday
Comtex SmarTrend(R) - Tue May 17, 1:24PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $27.90 to a high of $30.39. Yesterday, the shares gained 7.2%, which took the trading range above the 3-day high of $28.19 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 26.47 (-0.45)
Akorn meets 1Q profit forecasts
Automated Insights - Mon May 16, 4:03PM CDT
LAKE FOREST, Ill. (AP) _ Akorn Inc. (AKRX) on Monday reported first-quarter earnings of $41.9 million.
AKRX: 26.47 (-0.45)
SmarTrend Watching for Potential Pullback in Shares of Akorn After 14.34% Gain
Comtex SmarTrend(R) - Tue May 10, 3:26PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $24.43 to a high of $26.81. Yesterday, the shares gained 14.3%, which took the trading range above the 3-day high of $24.43 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 26.47 (-0.45)
Teva's (TEVA) Stock Gains on Q1 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Tue May 10, 6:18AM CDT
2016 is a transition year for Teva (TEVA) as it works on the integration of Actavis Generics and progresses with its branded pipeline.
AKRX: 26.47 (-0.45), TEVA: 50.99 (+0.60), AMPH: 18.73 (-0.27), NVS: 78.26 (-0.51)
Relypsa Soars 67% in Thursday Trading on Buyout Rumors
Arpita Dutt - Zacks Investment Research - Fri Apr 08, 8:50AM CDT
Relypsa (RLYP) shoots up on rumors that the company will be acquired.
AKRX: 26.47 (-0.45), RLYP: 31.98 (-0.01), AZN: 32.65 (-0.16), AMPH: 18.73 (-0.27)
3 Value Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 24, 8:21AM CDT
Image source: Pixabay. While many companies' shares are rising past their fair values now, others are trading at potentially bargain prices. The difficulty with bargain shopping, though, is that you may be understandably hesitant to buy stocks...
AKRX: 26.47 (-0.45), AMCX: 54.53 (+0.19), ICE: 284.05 (+2.03)
Akorn Has Returned 20.2% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Fri Feb 05, 10:52AM CST
SmarTrend identified a Downtrend for Akorn (NASDAQ:AKRX) on January 12th, 2016 at $31.33. In approximately 3 weeks, Akorn has returned 20.20% as of today's recent price of $25.00.
AKRX: 26.47 (-0.45)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 237.42 (+2.88), GNRX: 24.40 (-0.14), PRGO: 90.36 (-0.63), AXGN: 8.85 (-0.16), AKRX: 26.47 (-0.45), MYL: 41.82 (-0.54), TEVA: 51.00 (+0.61), AMPH: 18.73 (-0.27), NVS: 78.26 (-0.51)
Akorn Relaunches Ofloxacin Otic Solution
GlobeNewswire - Thu Aug 25, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has relaunched Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use.
AKRX: 26.47 (-0.45)
Akorn to Present at Morgan Stanley Global Healthcare Conference
GlobeNewswire - Wed Aug 24, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn's CEO, Raj Rai, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference.
AKRX: 26.47 (-0.45), MS: 31.81 (-0.25)
Akorn Appoints Robert Monahan as Senior Vice President of Corporate Development
GlobeNewswire - Thu Aug 18, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Rob Monahan has recently joined Akorn as Senior Vice President of Corporate Development.
WBA: 81.39 (+0.68), AKRX: 26.47 (-0.45)
Akorn Set to Possibly Rebound After Yesterday's Selloff of 1.91%
Comtex SmarTrend(R) - Wed Aug 10, 3:21PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $29.50 to a high of $31.00. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $30.11 on volume of 726,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 26.47 (-0.45)
Akorn Set to Possibly Rebound After Yesterday's Selloff of 4.36%
Comtex SmarTrend(R) - Thu Aug 04, 1:30PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $31.50 to a high of $35.40. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $32.41 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 26.47 (-0.45)
Downgrade Alert for Akorn (AKRX)
Comtex SmarTrend(R) - Wed Aug 03, 3:48AM CDT
Akorn (NASDAQ:AKRX) was downgraded from Outperform to Market Perform at Raymond James today. The stock closed yesterday at $32.89 on volume of 1.5 million shares, below average daily volume of 1.5 million. Akorn, Inc. develops, manufactures, and markets ophthalmic and injectable pharmaceutical products. The Company sells various diagnostic and therapeutic pharmaceutical products focused primarily on ophthalmology, anesthesia, antidotes, and rheumatology. Akorn also markets ophthalmic surgical instruments and other supplies, and provides contract manufacturing for third parties.
AKRX: 26.47 (-0.45)
Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.24 (-0.10), CPRX: 0.94 (-0.07), AKRX: 26.47 (-0.45), PCRX: 40.00 (+0.37)
Akorn Updates Form S-8 Status by Filing Form 10-Q's for First, Second and Third Quarters of 2015
GlobeNewswire - Thu Jun 02, 5:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has filed quarterly reports on Forms 10-Q with the Securities and Exchange Commission (SEC) for the quarters ended March 31, 2015, June 30, 2015 and September 30, 2015. The quarterly financial results that are included in the individual Forms 10-Q were previously filed by the Company in its comprehensive Form 10-K for the fiscal year 2015 that was filed with the SEC on May 10, 2016. The individual Forms 10-Q were filed solely in order to make effective the Company's Registration Statement on Form S-8, on which the Company's securities offered under its employee benefit plan are registered.
AKRX: 26.47 (-0.45)
Akorn to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that management will be presenting at the Jefferies 2016 Healthcare Conference and William Blair 36th Annual Growth Stock Conference in June.
AKRX: 26.47 (-0.45)
SmarTrend Watching for Potential Rebound in Shares of Akorn After 2.24% Loss
Comtex SmarTrend(R) - Thu May 26, 2:05PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $29.37 to a high of $30.51. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $30.27 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 26.47 (-0.45)
Akorn (AKRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:54AM CDT
As of late, it has definitely been a great time to be an investor in Akorn, Inc. (AKRX)
AKRX: 26.47 (-0.45)
Watch for Akorn to Potentially Pullback After Gaining 7.19% Yesterday
Comtex SmarTrend(R) - Tue May 17, 1:24PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $27.90 to a high of $30.39. Yesterday, the shares gained 7.2%, which took the trading range above the 3-day high of $28.19 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 26.47 (-0.45)
Akorn meets 1Q profit forecasts
Automated Insights - Mon May 16, 4:03PM CDT
LAKE FOREST, Ill. (AP) _ Akorn Inc. (AKRX) on Monday reported first-quarter earnings of $41.9 million.
AKRX: 26.47 (-0.45)
SmarTrend Watching for Potential Pullback in Shares of Akorn After 14.34% Gain
Comtex SmarTrend(R) - Tue May 10, 3:26PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $24.43 to a high of $26.81. Yesterday, the shares gained 14.3%, which took the trading range above the 3-day high of $24.43 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 26.47 (-0.45)
Teva's (TEVA) Stock Gains on Q1 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Tue May 10, 6:18AM CDT
2016 is a transition year for Teva (TEVA) as it works on the integration of Actavis Generics and progresses with its branded pipeline.
AKRX: 26.47 (-0.45), TEVA: 50.99 (+0.60), AMPH: 18.73 (-0.27), NVS: 78.26 (-0.51)
Relypsa Soars 67% in Thursday Trading on Buyout Rumors
Arpita Dutt - Zacks Investment Research - Fri Apr 08, 8:50AM CDT
Relypsa (RLYP) shoots up on rumors that the company will be acquired.
AKRX: 26.47 (-0.45), RLYP: 31.98 (-0.01), AZN: 32.65 (-0.16), AMPH: 18.73 (-0.27)
3 Value Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 24, 8:21AM CDT
Image source: Pixabay. While many companies' shares are rising past their fair values now, others are trading at potentially bargain prices. The difficulty with bargain shopping, though, is that you may be understandably hesitant to buy stocks...
AKRX: 26.47 (-0.45), AMCX: 54.53 (+0.19), ICE: 284.05 (+2.03)
Akorn Has Returned 20.2% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Fri Feb 05, 10:52AM CST
SmarTrend identified a Downtrend for Akorn (NASDAQ:AKRX) on January 12th, 2016 at $31.33. In approximately 3 weeks, Akorn has returned 20.20% as of today's recent price of $25.00.
AKRX: 26.47 (-0.45)
